PRINT THIS PAGE

In clinical studies, CIMZIA produced rapid and sustained improvements in pain, fatigue, and disability in many patients and contributed to an improvement in productivity within and outside the home.1-3

CIMZIA pivotal studies: Patient-reported outcomes (PROs)

One of the secondary objectives of the pivotal studies of CIMZIA was to assess the impact of CIMZIA on health-related outcomes of importance to patients with active rheumatoid arthritis (RA).2,4,5 Validated patient self-report instruments were used to assess patient outcomes at baseline and at multiple intervals until study completion or patient withdrawal.1,2,6

  • Pain, fatigue, disability, and health-related quality of life. PROs assessed in RAPID 1, RAPID 2, and FAST4WARD included physical function/disability (HAQ-DI), fatigue (FAS), arthritis pain (VAS), and health-related quality of life (SF-36). Published analyses of data from these assessments show that treatment with CIMZIA plus MTX (RAPID 1) and CIMZIA monotherapy (FAST4WARD) resulted in significant improvements in pain, fatigue, and disability as early as week 1.1,2,4
    Learn more
  • Productivity. RAPID 1 and RAPID 2 used the validated RA-specific Work Productivity Survey (WPS-RA) to assess the impact of CIMZIA plus methotrexate (MTX) on productivity outside and within the home. Published analysis of data from these assessments shows that CIMZIA plus MTX resulted in significant improvement over placebo plus MTX on all assessed measures of productivity.3

    NEXT: Pain, Fatigue, Disability, and Health-Related Quality of Life »